First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

Nature Cancer · Published 2026-06-08 · DOI 10.1038/s43018-026-01181-8

Free full text

Authors (12)

Peter Schmid, S.-A. Im, Zbigniew Nowecki, Piotr Jan Wysocki, Jacek Jassem, K.H. Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Schmid, P., Im, S., Nowecki, Z., et al. (2026). First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nature Cancer. https://doi.org/10.1038/s43018-026-01181-8

Related articles